MAPT and Alzheimer disease: Currently, positron-emission tomography (PET) imaging and cerebrospinal fluid (CSF) measures of β-Amyloid (Aβ) and Tau allow identification of pre-symptomatic individuals at risk of AD, improve diagnostic accuracy for symptomatic individuals, and help to stratify appropriate subjects for clinical trials [2, 3].